Haoyuan Pharmaceuticals: Plans to raise 50 million yuan to increase the capital of a subsidiary for project implementation.

Haoyuan Pharmaceuticals announced that the company plans to use 50 million yuan of the proceeds from the convertible bonds to increase the capital of its subsidiary, Europe Creative Biology, and implement the "European Creative Biology New Drug Technology Research and Development Center" project. The company has already signed a "Equity Transfer Agreement" with other shareholders of Europe Creative Biology, acquiring their equity. After the completion of the industrial and commercial change, Europe Creative Biology will become a wholly-owned subsidiary. This increase in capital has been approved by the Board of Directors' Audit Committee and the Board of Directors, and does not constitute a related party transaction or a significant asset restructuring. Europe Creative Biology had a revenue of 70.488 million yuan and a net profit of 0.8618 million yuan from January to September 2025.